Lucid Diagnostics Closes $18M Equity Offering Anchored by $15M Institutional Investor
Lucid Diagnostics, a PAVmed Inc. subsidiary, raised $18 million by selling 18 million common shares at $1.00 each in an underwritten direct offering backed by a $15 million anchor investor and support from a major existing shareholder. Proceeds will fund working capital and general corporate purposes.
1. Offering Details
Lucid Diagnostics executed an underwritten registered direct offering of 18 million common shares at $1.00 per share, generating approximately $18 million in gross proceeds before discounts and commissions with Canaccord Genuity and BTIG as joint bookrunners.
2. Investor Participation
The offering attracted a $15 million anchor investment from a fundamental institutional investor, supplemented by participation from a major existing shareholder, highlighting institutional confidence in Lucid's cancer prevention diagnostics platform.
3. Use of Proceeds
Lucid Diagnostics plans to allocate net proceeds to working capital and general corporate purposes, supporting ongoing operations and potential advancement of its EsoGuard® Esophageal DNA Test and EsoCheck® collection device.
4. Implications for PAVmed Inc.
For PAVmed Inc., Lucid Diagnostics' parent, the infusion of capital may extend operational runway and reduce reliance on future financings, likely influencing PAVmed's valuation and investor sentiment.